Thinly traded Novocure (NASDAQ:NVCR) jumps 66% premarket on robust volume in response to its announcement of positive long-term data from a 695-subject Phase 3 clinical trial, EF-14, assessing Optune added to standard chemotherapy temozolomide in newly diagnosed glioblastoma (GBM) patients.
The two-year survival rate increased to 43% from 30% in patients treated with Optune plus chemo compared to chemo alone. The five-year survival increased to 13% from 5%. The company says these are the best results reported for newly diagnosed GBM patients in a late-stage study. (hazard ratio = 0.63; p<0.00006).
Optune is a non-invasive device that creates alternating "wave-like" electric fields called Tumor Treating Fields (TTFields). It delivers its therapy to brain tumors through four transducer arrays placed on the scalp.